EMElyssa B. Margolis

Elyssa B. Margolis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elyssa B. Margolis has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mu-Opioid Receptor in Habenula Circuits as a Substrate for Psychiatric Disorders and Addiction

    by Emmanuel Darcq, Kevin Coffey, Ines Ibaez-Tallon, Elyssa B. Margolis, Kristen R. Maynard, Thomas S. Hnasko

    The habenula is a critical regulator of affect, negative reinforcement, avoidance, and coping behavior. It is thus unsurprising that accumulating evidence supports pivotal roles for habenular circuits in the expression of major psychiatric illnesses including depression and addiction. Though high levels of mu-opioid receptors (MORs) were identified in the habenula more than a generation ago, the functional effects of MORs on habenular circuits remained largely unexplored due to challenges of selectively targeting this small and heterogeneous brain structure. In this SfN mini-symposium report, we highlight studies that resolve how MOR is distributed across medial and lateral habenular subnuclei and how MOR expression maps onto molecularly defined habenular cell types. We further describe some of the habenula-intersecting circuits that express MORs and how MOR signaling modulates neural activity and neurotransmission within these unique habenular circuits and cell types. Going beyond cellular-level effects of MOR signaling, we illustrate how neural activity in the habenula can influence affect and behaviors associated with opioid analgesia, opioid seeking, opioid dependence, and opioid withdrawal. Drawing on works outside the opioid field, we suggest commonalities through which drugs of abuse may influence habenula circuits to induce states of negative affect that contribute to continued drug use or relapse. Finally, we discuss how better understanding the molecular and functional properties of habenular cell types and circuits can identify new druggable targets, such as the orphan receptors GPR151 and GPR139, for the treatment of pain, mood disorders, or opioid and other substance use disorders.

  • Open Access

    Mu Opioid Receptor mRNA and Protein Localization Across the Rat and Mouse Habenula

    by Aashka K. Popat, Rhiana C. Simon, Beatriz B. Aoyama, Ahana Wokhlu, Aliza T. Ehrlich, Corey C. Harwell, Elyssa B. Margolis

    The habenula (Hb) has high‐intensity mu opioid binding and receptor (MOR) expression. It contains medial and lateral subdivisions (MHb and LHb, respectively), yet the details of MOR localization across these regions remain debated. MHb and LHb participate in largely non‐overlapping neural circuits; therefore, accurately resolving MOR expression across them is critical for understanding how MOR ligands impact behaviors. Here we utilized in situ hybridization (ISH) and immunocytochemistry (ICC) to systematically map Oprm1 mRNA and MOR protein throughout the habenular complex. We studied rat and mouse tissue to evaluate expression across two common research species. We also performed parallel mapping in Oprm1‐ Venus/Venus mice. Importantly, we found mRNA and protein in both MHb and LHb in both species. In rat, 39 ± 3% and 21 ± 4% of cells expressed Oprm1 in MHb and LHb, respectively. These proportions were greater in mouse: 57 ± 1% (MHb) and 32 ± 4% (LHb). Oprm1 puncta per positive cell were greater in MHb compared to LHb for both rat and mouse ( p < 0.0001). The highest intensity labeling was localized along the lateral edge of the MHb for all methods. ICC showed MOR localized to fibers and somata in both regions. In LHb, MOR labeling was most dense in intermediate sections along the anterior‐posterior (AP) axis. In rats we also observed greater labeling in dorsal LHb at intermediate AP levels and medial LHb more posteriorly. These results indicate that both MHb and LHb can contribute to MOR‐mediated actions through their respective circuits.


  • Open Access

    Mu opioid receptor mRNA and protein localization across the rat and mouse habenula

    by Aashka K. Popat, Rhiana C. Simon, Beatriz B. Aoyama, Ahana Wokhlu, Aliza T. Ehrlich, Corey C. Harwell, Elyssa B. Margolis

    The habenula (Hb) has high intensity mu opioid binding and receptor (MOR) expression. It contains medial and lateral subdivisions (MHb and LHb, respectively), yet the details of MOR localization across these regions remains debated. MHb and LHb participate in largely non-overlapping neural circuits, therefore accurately resolving MOR expression across them is critical for understanding how MOR ligands impact behaviors. Here we utilized in situ hybridization (ISH) and immunocytochemistry (ICC) to systematically map Oprm1 mRNA and MOR protein throughout the habenular complex. We studied rat and mouse tissue to evaluate expression across two common research species. We also performed parallel mapping in Oprm1- Venus/Venus mice. Importantly, we found mRNA and protein in both MHb and LHb in both species. In rat, 39 ± 3% and 21 ± 4% of cells expressed Oprm1 in MHb and LHb, respectively. These proportions were greater in mouse: 57 ± 1% (MHb) and 32 ± 4% (LHb). Oprm1 puncta per positive cell were greater in MHb compared to LHb for both rat and mouse ( p < 0.0001). The highest intensity labeling was localized along the lateral edge of the MHb for all methods. ICC showed MOR localized to fibers and somata in both regions. In LHb, MOR labeling was most dense in intermediate sections along the anterior-posterior (AP) axis. In rats we also observed greater labeling in dorsal LHb at intermediate AP levels and medial LHb more posteriorly. These results indicate that both MHb and LHb can contribute to MOR mediated actions through their respective circuits. Key Points: Mu opioid receptor mRNA and protein are expressed in both the medial and lateral habenulae in rat and mouse. In the medial habenula, most mu opioid receptor mRNA and protein was detected along its lateral border. Across samples, Oprm1+ cells in the MHb contained more mRNA puncta per cell compared to lateral habenula cells.


  • Open Access

    CHCHD2 mutant mice link mitochondrial deficits to PD pathophysiology

    by Szu-Chi Liao, Kohei Kano, Sadhna Phanse, Mai Nguyen, Elyssa Margolis, YuHong Fu, Jonathan X. Meng, Mohamed Taha Moutaoufik, Zac Chatterton, Tatiana Saccon, et al.

    Mitochondrial dysfunction is a hallmark of Parkinson’s disease (PD), but the mechanisms by which it drives autosomal dominant and idiopathic forms of PD remain unclear. To investigate this, we generated and performed a comprehensive phenotypic analysis of a knock-in mouse model carrying the T61I mutation in the mitochondrial protein CHCHD2 (coiled-coil–helix–coiled-coil–helix domain–containing 2), which causes late-onset symptoms indistinguishable from idiopathic PD. We observed pronounced mitochondrial disruption in substantia nigra dopaminergic neurons, including distorted ultrastructure and CHCHD2 aggregation, as well as disrupted mitochondrial protein-protein interactions in brain lysates. These abnormalities were associated with a whole-body metabolic shift toward glycolysis, elevated mitochondrial reactive oxygen species (ROS), and progressive accumulation of aggregated α-synuclein. In idiopathic PD, CHCHD2 gene expression also correlated with α-synuclein levels in vulnerable dopaminergic neurons, and CHCHD2 protein accumulated in early Lewy aggregates. These findings delineate a pathogenic cascade in which CHCHD2 accumulation impairs mitochondrial respiration and increases ROS production, driving α-synuclein aggregation and neurodegeneration.


  • Open Access

    Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration

    by Katerina Rademacher, Zak Doric, Dominik Haddad, Aphroditi Mamaligas, Szu-Chi Liao, Rose Creed, Kohei Kano, Zac Chatterton, Yuhong Fu, Joseph H Garcia, et al.

    Parkinson’s disease (PD) is characterized by the death of substantia nigra pars compacta (SNc) dopamine (DA) neurons, but the pathophysiological mechanisms that precede and drive their death remain unknown. The activity of DA neurons is likely altered in PD, but we understand little about if or how chronic changes in activity may contribute to degeneration. To address this question, we developed a chemogenetic (DREADD) mouse model to chronically increase DA neuron activity and confirmed this increase using ex vivo electrophysiology. Chronic hyperactivation of DA neurons resulted in prolonged increases in locomotor activity during the light cycle and decreases during the dark cycle, consistent with chronic changes in DA release and circadian disturbances. We also observed early, preferential degeneration of SNc projections, recapitulating the PD hallmarks of selective vulnerability of SNc axons and the comparative resilience of ventral tegmental area axons. This was followed by the eventual loss of midbrain DA neurons. Continuous DREADD activation resulted in a sustained increase in baseline calcium levels, supporting a role for increased calcium in the neurodegeneration process. Finally, spatial transcriptomics from DREADD mice examining midbrain DA neurons and striatal targets, and cross-validation with human patient samples, provided insights into potential mechanisms of hyperactivity-induced toxicity and PD. Our results thus reveal the preferential vulnerability of SNc DA neurons to increased neural activity and support a potential role for increased neural activity in driving degeneration in PD.


  • Open Access

    A switch in kappa opioid receptor signaling from inhibitory to excitatory induced by stress in a subset of cortically-projecting dopamine neurons

    by Elyssa B. Margolis

    Background: The kappa opioid receptor (KOR) has shown potential as a therapeutic target for several neuropsychiatric disorders including major depressive disorder, chronic pain, and substance use disorder. Signaling of G protein coupled receptors (GPCRs) like the KOR is generally thought to change in magnitude, not valence, with behavior states. Here we investigated KOR modulation of ventral tegmental area (VTA) neurons following an acute, behaviorally aversive manipulation. Methods: KOR agonist responses were measured with whole cell recordings in acute brain slices containing the VTA from male and female rats. Slices were made ex vivo rapidly induced a similar switch in KOR signaling. This effect was observed specifically in dorsal medial prefrontal cortex (dmPFC) projecting VTA neurons, but not in other projections. Behaviorally, foot shock stress produced a loss of conditioned place aversion to intra-VTA KOR activation. Conclusions: After acute aversive stress, KOR activation in the VTA excites, rather than inhibits, dmPFC-projecting VTA dopamine neurons. This change can be generated by activating the CRF system and interferes with the aversiveness of VTA KOR activation.


  • Open Access

    Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration

    by Katerina Rademacher, Zak Doric, Dominik Haddad, Aphroditi Mamaligas, Szu-Chi Liao, Rose B Creed, Kohei Kano, Zac Chatterton, YuHong Fu, Joseph H Garcia, et al.

    Parkinson’s disease (PD) is characterized by the death of substantia nigra (SNc) dopamine (DA) neurons, but the pathophysiological mechanisms that precede and drive their death remain unknown. The activity of DA neurons is likely altered in PD, but we understand little about if or how chronic changes in activity may contribute to degeneration. To address this question, we developed a chemogenetic (DREADD) mouse model to chronically increase DA neuron activity, and confirmed this increase using ex vivo electrophysiology. Chronic hyperactivation of DA neurons resulted in prolonged increases in locomotor activity during the light cycle and decreases during the dark cycle, consistent with chronic changes in DA release and circadian disturbances. We also observed early, preferential degeneration of SNc projections, recapitulating the PD hallmarks of selective vulnerability of SNc axons and the comparative resilience of ventral tegmental area axons. This was followed by eventual loss of midbrain DA neurons. Continuous DREADD activation resulted in a sustained increase in baseline calcium levels, supporting a role for increased calcium in the neurodegeneration process. Finally, spatial transcriptomics from DREADD mice examining midbrain DA neurons and striatal targets, and cross-validation with human patient samples, provided insights into potential mechanisms of hyperactivity-induced toxicity and PD. Our results thus reveal the preferential vulnerability of SNc DA neurons to increased neural activity, and support a potential role for increased neural activity in driving degeneration in PD.


  • Open Access

    Structure-guided design of partial agonists at an opioid receptor

    by Balazs R. Varga, Sarah M. Bernhard, Amal El Daibani, Saheem A. Zaidi, Jordy H. Lam, Jhoan Aguilar, Kevin Appourchaux, Antonina L. Nazarova, Alexa Kouvelis, Ryosuke Shinouchi, et al.

    Chronic pain and opioid overdose deaths highlight the need for non-addictive analgesics with novel mechanisms. The δ opioid receptor (δOR) is a promising target, as it lacks the respiratory depression associated with µ opioid receptor (µOR) agonists. However, early δOR full agonists caused seizures, limiting their clinical use. Partial δOR agonists may offer more controlled receptor activation than full agonists, but their development has been hindered by uncertainty regarding the molecular mechanism of partial agonism. Here we show that C6-Quino, a bitopic ligand developed through structure-based design, acts as a selective δOR partial agonist. Functional studies reveal that C6-Quino shows differential activity at G-protein and arrestin pathways and interacts with the sodium binding pocket, confirmed through cryo-EM analysis. C6-Quino demonstrates oral activity, analgesic activity in chronic pain models without causing δOR-related seizures and µOR-related adverse effects which have limited opioid usage in recent times. This discovery outlines a new strategy for developing δOR-targeted analgesics and provides a framework for optimizing signaling profiles of other Class A GPCRs.


  • Open Access

    CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism

    by Szu-Chi Liao, Kohei Kano, Sadhna Phanse, Mai Nguyen, Elyssa Margolis, YuHong Fu, Jonathan Meng, Mohamed Taha Moutaoufik, Zac Chatterton, Hiroyuki Aoki, et al.

    Mutations in the mitochondrial cristae protein CHCHD2 lead to a late-onset autosomal dominant form of Parkinson’s disease (PD) which closely resembles idiopathic PD, providing the opportunity to gain new insights into the mechanisms of mitochondrial dysfunction contributing to PD. To begin to address this, we used CRISPR genome-editing to generate CHCHD2 T61I point mutant mice. CHCHD2 T61I mice had normal viability, and had only subtle motor deficits with no signs of premature dopaminergic (DA) neuron degeneration. Nonetheless, CHCHD2 T61I mice exhibited robust molecular changes in the brain including increased CHCHD2 insolubility, accumulation of CHCHD2 protein preferentially in the substantia nigra (SN), and elevated levels of α-synuclein. Metabolic analyses revealed an increase in glucose metabolism through glycolysis relative to the TCA cycle with increased respiratory exchange ratio, and immune-electron microscopy revelated disrupted mitochondria in DA neurons. Moreover, spatial genomics revealed decreased expression of mitochondrial complex I and III respiratory chain proteins, while proteomics revealed increased respiratory chain and other mitochondrial protein-protein interactions. As such, the CHCHD2 T61I point-mutation mice exhibit robust mitochondrial disruption and a consequent metabolic shift towards glycolysis. These findings thus establish CHCHD2 T61I mice as a new model for mitochondrial-based PD, and implicate disrupted respiratory chain function as a likely causative driver.


  • Open Access

    Structure-Guided Design of Partial Agonists at an Opioid Receptor

    by Tao Che, Balazs Varga, Sarah M Bernhard, Amal El Daibani, Saheem Zaidi, Jordy Lam, Jhoan Aguilar, Kevin Appourchaux, Antonina Nazarova, Alexa Kouvelis, et al.

    The persistence of chronic pain and continuing overdose deaths from pain-relieving opioids targeting µ opioid receptor (µOR) have fueled the need for reliable long-term analgesics which use different targets and mechanisms. The δ opioid receptor (δOR) is a potential alternative target for non-addictive analgesics to alleviate chronic pain, made more attractive by its lack of respiratory depression associated with µOR agonists. However, early δOR full agonists were found to induce seizures, precluding clinical use. Partial δOR agonists may offer more controlled activation of the receptor compared to full agonists, but the development of such ligands has been hindered by uncertainty over the molecular mechanism mediating partial agonism. Using a structure-based approach, we explored the engagement of the sodium binding pocket in δOR and developed a bitopic ligand, C6-Quino, predicted to be a selective δOR partial agonist. Functional studies of C6-Quino revealed that it displayed δOR partial agonist activity at both G-protein and arrestin pathways. Its interaction with the sodium pocket was confirmed and analyzed using a single particle cryo-EM. Additionally, C6-Quino demonstrated favorable chemical and physiological properties like oral activity, and analgesic activity in multiple chronic pain models. Notably, µOR-related hyperlocomotion and respiratory depression, and δOR-related convulsions, were not observed at analgesic doses of C6-Quino. This fundamentally new approach to designing δOR ligands provides a blueprint for the development of partial agonists as safe analgesics and acts as a generic method to optimize signaling profiles of other Class A GPCRs.